Lupron to prevent menstrual bleeding or uterine bleeding during cancer therapy
Posted May 29 2011 6:09pm
Patients who are severely thrombocytopenic are at risk of bleeding and when they are female, rendering them amenorrheic is of immediate clinical benefit. Leukemic patients are often rendered amenorrheic to avoid bleeding complicaitons, if the chemotherapy itself does not do so. In endomteriosis, amenorrhea occurrs on Lupron in 74% and 98% of the patients after the first and second treatment months respectively. Most of the remaining patients report episodes of only light bleeding or spotting.
This practice is quite widespread and supported by a number of observational and retrospective studies.